publication venue for
- Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality.. 11:97-107. 2024
- Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study.. 11:814-822. 2024
- Cognitive Performance and Incident Alzheimer's Dementia in Men Versus Women.. 11:162-170. 2024
- Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults.. 11:339-347. 2024
- Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4.. 11:831-837. 2024
- Who Benefited Most from the Internet-Based Conversational Engagement RCT (I-CONECT)? Application of the Personalized Medicine Approach to a Behavioral Intervention Study.. 11:639-648. 2024
- Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease.. 10:112-119. 2023
- Editorial: Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness.. 10:5-6. 2023
- Geroscience and Alzheimer's Disease Drug Development.. 10:620-632. 2023
- Lecanemab: Appropriate Use Recommendations.. 10:362-377. 2023
- Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer's Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Models and a Probability Calculator.. 10:301-313. 2023
- Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics.. 10:633-646. 2023
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.. 10:34-40. 2023
- Validity of Normative Volumetric Estimates from Open Access Software in Amnestic Mild Cognitive Impairment.. 10:236-243. 2023
- Aducanumab: Appropriate Use Recommendations Update.. 9:221-230. 2022
- Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid.. 9:617-624. 2022
- Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults.. 9:286-296. 2022
- Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.. 9:569-579. 2022
- Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.. 9:507-522. 2022
- Diversifying Recruitment Registries: Considering Neighborhood Health Metrics.. 9:119-125. 2022
- Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults.. 9:297-305. 2022
- Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults.. 9:801-808. 2022
- Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials.. 9:241-246. 2022
- Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial.. 9:22-29. 2022
- A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment.. 8:135-141. 2021
- Aducanumab: Appropriate Use Recommendations.. 8:398-410. 2021
- Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.. 8:520-533. 2021
- Current State of Self-Administered Brief Computerized Cognitive Assessments for Detection of Cognitive Disorders in Older Adults: A Systematic Review.. 8:267-276. 2021
- Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.. 8:414-424. 2021
- Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data.. 8:257-262. 2021
- Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.. 8:199-209. 2021
- Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.. 8:306-312. 2021
- The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial.. 8:59-67. 2021
- The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program.. 8:286-291. 2021
- Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.. 7:213-218. 2020
- Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).. 7:219-225. 2020
- Self-Administered Cognitive Testing by Older Adults At-Risk for Cognitive Decline.. 7:283-287. 2020
- TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology.. 7:226-233. 2020
- The Future of Anti-Amyloid Trials.. 7:146-151. 2020
- The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.. 7:234-241. 2020
- The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview.. 7:208-212. 2020
- Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.. 6:112-120. 2019
- What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.. 5:171-174. 2018
- Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly.. 4:81-86. 2017
- Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries.. 4:3-11. 2017
- EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.. 4:116-124. 2017
- Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.. 4:236-241. 2017
- Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.. 3:114-120. 2016
- The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials.. 3:8-12. 2016
- A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).. 2:227-241. 2015
- The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease.. 2:242-253. 2015
- Establishing Clinical Relevance in Preclinical Alzheimer's Disease.. 2:85-87. 2015
- Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer's Disease: Transforming Functional Scores into Levels of Dependence.. 2:115-120. 2015
- The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.. 1:181-202. 2014
- Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making.. 1:117-123. 2014
- Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research.. 7:206-207.
- Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease.. 11:823-830.